

ACHILLION PHARMACEUTICALS INC
Form SC 13G
September 04, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. ____) *

ACHILLION PHARMACEUTICALS, INC.

(Name of Issuer)

COMMON STOCK, PAR VALUE \$0.001 PER SHARE

(Title or Class of Securities)

00448Q201

(CUSIP Number)

August 12, 2008

(Date of Event Which Requires Filing of this Statement)

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the Notes).

CUSIP No.

13G

Page 2 of 8

1 NAMES OF REPORTING PERSONS

S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

Investor AB

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐(b) ☒

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Sweden

5 SOLE VOTING POWER

NUMBER OF

3,901,915

SHARES

6 SHARED VOTING POWER

BENEFICIALLY

OWNED BY

0

EACH

7 SOLE DISPOSITIVE POWER

REPORTING

PERSON

3,901,915

8 SHARED DISPOSITIVE POWER

WITH:

0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,901,915

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

☐

N/A

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

14.0%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO

** Consists of 2,323,660 shares of Common Stock, 580,915 shares of Common Stock subject to currently exercisable warrants, and units subject to warrants (the Unit Warrants) exercisable for 797,872 shares of Common Stock and warrants to purchase 199,468 shares of Common Stock. The Unit Warrants will be exercisable from February 12, 2009 through August 12, 2009, and the underlying warrants that may be acquired upon exercise of the Unit Warrants, if so acquired, will be immediately exercisable.

CUSIP No.

13G

Page 3 of 8

1 NAMES OF REPORTING PERSONS

S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

Investor Growth Capital Limited

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐(b) ☒

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Guernsey

5 SOLE VOTING POWER

NUMBER OF

2,731,341

SHARES

6 SHARED VOTING POWER

BENEFICIALLY

OWNED BY

0

EACH

7 SOLE DISPOSITIVE POWER

REPORTING

PERSON

2,731,341

8 SHARED DISPOSITIVE POWER

WITH:

0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,731,341

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

☐

N/A

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.9%**

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

OO

*** Consists of 1,626,562 shares of Common Stock, 406,641 shares of Common Stock subject to currently exercisable warrants, and units subject to warrants (the Unit Warrants) exercisable for 558,510 shares of Common Stock and warrants to purchase 139,628 shares of Common Stock. The Unit Warrants will be exercisable from February 12, 2009 through August 12, 2009, and the underlying warrants that may be acquired upon exercise of the Unit Warrants, if so acquired, will be immediately exercisable.

CUSIP No.

13G

Page 4 of 8

ITEM 1 (a). NAME OF ISSUER:

The name of the issuer is Achillion Pharmaceuticals, Inc. (the Issuer).

ITEM 1 (b). ADDRESS OF ISSUER S PRINCIPAL EXECUTIVE OFFICES:

The Issuer s principal executive office is located at 300 George Street, New Haven, CT 06511.

ITEM 2 (a). NAME OF PERSON FILING:

This Schedule 13G is being jointly filed by:

(i) Investor AB, a limited liability company incorporated under the laws of Sweden, with respect to the shares of Common Stock (as defined below) of the Issuer held by Investor Growth Capital Limited (Investor Growth Capital) and Investor Group, L.P. Investor Growth Capital, a Guernsey company, is an indirect wholly-owned subsidiary of Investor AB. Investor Group, L.P. is a limited partnership of which Investor AB is the indirect general partner. Investor AB may be deemed to beneficially own the securities held by Investor Growth Capital and Investor Group, L.P.

(ii) Investor Growth Capital with respect to shares of Common Stock of the Issuer that it holds directly.

ITEM 2 (b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

Arsenalsgatan 8c

S-103

32 Stockholm, Sweden

ITEM 2 (c). CITIZENSHIP:

(i) Investor AB is a limited liability company incorporated under the laws of Sweden.

(ii) Investor Growth Capital is a Guernsey company.

ITEM 2 (d). TITLE OF CLASS OF SECURITIES:

Common Stock, par value \$0.001 per share (the Common Stock)

ITEM 2 (e). CUSIP NUMBER:

00448Q201

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- (a) ☐ Broker or dealer registered under Section 15 of the Exchange Act.
- (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c) ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) ☐ Investment company registered under Section 8 of the Investment Company Act.
- (e) ☐ Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
- (f) ☐ Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
- (g) ☐ Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G).
- (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
- (j) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

ITEM 4. OWNERSHIP:

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

Investor AB

(a) Amount beneficially owned:

3,901,915 shares

(b) Percent of class:

14.0%

(c) Number of shares as to which such person has:

(i) Sole power to vote or direct the vote:

3,901,915 shares

(ii) Shared power to vote or direct the vote:

None

(iii) Sole power to dispose or to direct the disposition of:

3,901,915 shares

(iv) Shared power to dispose or to direct the disposition of:

None

Investor Growth Capital

(a) Amount beneficially owned:

2,731,341 shares

(b) Percent of class:

9.9%

(c) Number of shares as to which such person has:

(i) Sole power to vote or direct the vote:

2,731,341 shares

(ii) Shared power to vote or direct the vote:

None

(iii) Sole power to dispose or to direct the disposition of:

2,731,341 shares

(iv) Shared power to dispose or to direct the disposition of:

None

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following " " .

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

See Item 2(a) and 4.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP:

Not applicable.

ITEM 10. CERTIFICATION:

By signing below, each of the undersigned certify that, to the best of the undersigned's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No.

13G
SIGNATURE

Page 6 of 8

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 3, 2008

INVESTOR AB

/s/ Michael Oporto
Michael Oporto, Attorney-in-Fact

/s/ Henry Gooss
Henry Gooss, Attorney-in-Fact

INVESTOR GROWTH CAPITAL LIMITED

/s/ Michael Oporto
Michael Oporto, Attorney-in-Fact

/s/ Henry Gooss
Henry Gooss, Attorney-in-Fact

CUSIP No.

13G
EXHIBIT INDEX

Page 7 of 8

Exhibit 1. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

CUSIP No.

13G

Page 8 of 8
Exhibit 1

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or its knows or has reason to believe that such information is inaccurate.

Date: September 3, 2008

INVESTOR AB

/s/ Michael Oporto
Michael Oporto, Attorney-in-Fact

/s/ Henry Gooss
Henry Gooss, Attorney-in-Fact

INVESTOR GROWTH CAPITAL LIMITED

/s/ Michael Oporto
Michael Oporto, Attorney-in-Fact

/s/ Henry Gooss
Henry Gooss, Attorney-in-Fact